Haemonetics Company Insiders

Haemonetics' latest congressional trading

Haemonetics Management Team Effectiveness

The company has Return on Asset of 0.0665 % which means that on every $100 spent on assets, it made $0.0665 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1883 %, implying that it generated $0.1883 on every 100 dollars invested. Haemonetics' management efficiency ratios could be used to measure how well Haemonetics manages its routine affairs as well as how well it operates its assets and liabilities. As of July 14, 2025, Return On Tangible Assets is expected to decline to 0.05. In addition to that, Return On Capital Employed is expected to decline to 0.07. At present, Haemonetics' Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 981.7 M, whereas Other Current Assets are forecasted to decline to about 56.6 M. The current year's Net Income Applicable To Common Shares is expected to grow to about 139.3 M, whereas Common Stock Shares Outstanding is forecasted to decline to about 42.5 M.

Haemonetics Workforce Comparison

Haemonetics Profit Margins

The company has Net Profit Margin of 0.12 %, which implies that it may need a different competitive strategy as even a very small decline in it revenue may erase profits and result in a net loss. This is way below average. In the same way, it shows Net Operating Margin of 0.17 %, which entails that for every 100 dollars of revenue, it generated $0.17 of operating income.

Haemonetics Insider Trading History

Haemonetics Notable Stakeholders

The success or failure of an entity such as Haemonetics often depends on how effective the management is. Haemonetics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Haemonetics management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Haemonetics management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

Please note, the presentation of Haemonetics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Haemonetics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Haemonetics' management manipulating its earnings.

When running Haemonetics' price analysis, check to measure Haemonetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Haemonetics is operating at the current time. Most of Haemonetics' value examination focuses on studying past and present price action to predict the probability of Haemonetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Haemonetics' price. Additionally, you may evaluate how the addition of Haemonetics to your portfolios can decrease your overall portfolio volatility.